Aileron Therapeutics, Inc. (ALRN) financial statements (2020 and earlier)

Company profile

Business Address 490 ARSENAL WAY
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments252151
Cash and cash equivalents71112
Short-term investments181039
Restricted cash and investments000
Other undisclosed current assets211
Total current assets:262252
Noncurrent Assets
Operating lease, right-of-use asset6
Property, plant and equipment070
Restricted cash and investments11 
Other noncurrent assets011
Total noncurrent assets:791
TOTAL ASSETS:343053
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities443
Accounts payable222
Accrued liabilities101
Employee-related liabilities111
Debt0  
Other undisclosed current liabilities222
Total current liabilities:655
Noncurrent Liabilities
Long-term debt and lease obligation55 
Long-term debt, excluding current maturities 5 
Operating lease, liability5
Total noncurrent liabilities:55 
Total liabilities:11115
Stockholders' equity
Stockholders' equity attributable to parent232048
Common stock000
Additional paid in capital214188185
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(191)(168)(137)
Total stockholders' equity:232048
TOTAL LIABILITIES AND EQUITY:343053

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses(30)(32)(23)
Operating loss:(30)(32)(23)
Loss before gain (loss) on sale of properties:(30)(32)(23)
Other undisclosed net income00 
Net loss:(30)(32)(23)
Other undisclosed net income attributable to parent0 0
Net loss attributable to parent:(29)(32)(23)
Preferred stock dividends and other adjustments  (0)
Net loss available to common stockholders, diluted:(29)(32)(23)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(30)(32)(23)
Comprehensive loss:(30)(32)(23)
Other undisclosed comprehensive income, net of tax, attributable to parent000
Comprehensive loss, net of tax, attributable to parent:(29)(32)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: